drugset / Trial / NCT07634198
A Clinical Study of YK-1169 Versus Ceftazidime-Avibactam in Adults With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia
RandomizedParallel-groupDouble-blindTreatment
Summary
To evaluate the all-cause mortality rate at Day 28 in the YK-1169 group versus the ceftazidime-avibatan injection group in the mITT population.
Timeline
- Start
- 2026-06-04
- Primary completion
- 2028-04-01
- Completion
- 2028-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ceftazidime-avibactam | Other / unclassified | 2.5 g | Intravenous |
| Subject | YK-1169 | Unknown | 2.5 g | Intravenous |